Monrovia, Liberia- The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) has welcomed U.S. Ambassador Mark Toner’s recent visit to its JFK clinical research site in Monrovia.
Ambassador Toner was a accompanied by Minister of Health Dr. Louis Kpoto and JFK Hospital CEO Dr. Linda Birch.
According to PREVAIL release, Ambassador Toner’s visit underscored the importance of collaborative efforts in combating infectious diseases.
The team shared updates on their groundbreaking scientific work since PREVAIL’s establishment in 2014, including pioneering trials on Ebola vaccines to the ongoing phase 2a studies on Lassa Fever, PREVAIL has become a beacon of hope and innovation in Liberia’s health sector.
The PREVAIL JFK clinical site, located within the Right Wing of the JFK Memorial Hospital, serves as a hub for vital clinical research.
During the visit, PREVAI Director highlighted the impressive progress made: four completed protocol studies, 11 ongoing protocol studies, and several more in the pipeline.
According to the release, this partnership between the U.S. and Liberia exemplifies the power of unity in addressing public health challenges.
Ambassador Toner extolled PREVAIL’s commitment to improving health outcomes in Liberia.
“Your work is not just about research; it’s about saving lives and building a healthier future for all Liberians,” he remarked, inspiring the team to continue their vital mission.
The collaboration between PREVAIL and its partners promises to pave the way for innovative solutions to infectious diseases, fostering a healthier tomorrow.
